Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

Journal of the American Academy of Dermatology

Volumn 47, Issue 4 SUPPL., 2002, Pages

  Berman, Brian ^a   Kaufman, Joely ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; EDEMA; EROSION; ERYTHEMA; FEMALE; HUMAN; HYPERPIGMENTATION; KELOID; MALE; PIGMENT DISORDER; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SKIN IRRITATION;

EID: 0036785057     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126585     Document Type: Article

References (17)

1. Oluwasanmi JO. Keloids in the African. Clin Plast Surg 1974;1:179-95.
2. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alpha-2b injections. J Am Acad Dermatol 1997;37:755-7.
3. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and s-28463. J Invest Dermatol 1998;110:734-9.
4. Berman B, Duncan MR. Inhibition of dermal fibrosis by interferons. In: Nickoloff BJ, editor. Dermal immune system. Ann Arbor (MI): CRC Press, Inc; 1993. p. 209-26.
5. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon-alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694-706.
6. Nedelec B, Dodd CM, Scott PG, Ghahary A, Tredget EE. Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo. Wound Repair Regen 1998;6:202-12.
7. Ghahary A, Scott PG, Malhotra S. Differential expression of type I and type III procollagen mRNA in human hypertrophic burn fibroblasts. Biomed Lett 1992;47:169.
8. Wahl SM, Wahl LM, McCarthy JB. Lymphocyte mediated activation of fibroblast proliferation and collagen production. J Immunol 1978;121:942-6.
9. Kamin AJ. The etiology of keloids. A review of the literature and a new hypothesis. S Afr Med J 1974;38:913-6.
10. McCauley RL, Chopra V, Li Y, Dobson MC. Altered cytokine production in black patients with keloids. J Clin Immunol 1992;12:300-8.
11. Duncan MR, Perlish JS, Fleishmajer R. Lymphokine/monokine inhibition of fibroblast proliferation and collagen production: role of progressive systemic sclerosis. J Invest Dermatol 1984;83:377-84.
12. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984;74:1112-6.
13. Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 1997;77:701-30.
14. Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994;14:81-5.
15. Berman B, Bieley HC. Keloids. J Am Acad Dermatol 1995;33:117-23.
16. Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg 1989;84:827-35.
17. Darzi MA, Chowdri NA, Kaul SK, Khan M. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow up study. Br J Plast Surg 1992;45:374-9.